1Q Revenues: $1.1 billion (+6%)
1Q Earnings: $67.9 million (loss of $76.6 million in 1Q13)
Comments: Growth in the quarter was driven by Specialty Injectable Pharmaceuticals (SIP), up 10% to $716.3 million, driven mainly by improved pricing and increased volume, as well as competitor supply issues in the U.S. This growth was partially offset by the decline of U.S. sales of oncolytic docetaxel, the device ship-hold effected in February 2013, and foreign currency. Quality and product related charges contributed to losses in 1Q13.